Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.37 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.34 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.34 |
| ▸ | WNT1 | P04628 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16809855 | 0.76 | LRRK2 (0.39) | LRRK2PRMT5WDR77WNT1GSK3B | |
| SCHEMBL24582729 | 0.74 | LRRK2 (0.39) | LRRK2PRMT5WDR77WNT1GSK3B | |
| SCHEMBL14701579 | 0.74 | CYP11B1 (0.41) | LRRK2 | |
| SCHEMBL16469156 | 0.74 | LRRK2 (0.39) | LRRK2PRMT5WDR77WNT1GSK3B | |
| SCHEMBL18338504 | 0.74 | LRRK2 (0.39) | LRRK2PRMT5WDR77WNT1GSK3B | |
| SCHEMBL24582838 | 0.73 | PRMT5 (0.47) | LRRK2PRMT5WDR77WNT1GSK3B | |
| SCHEMBL25669840 | 0.71 | KDM5B (0.41) | LRRK2 | |
| SCHEMBL23109057 | 0.71 | KDM5B (0.41) | LRRK2 | |
| SCHEMBL25484494 | 0.70 | — | — | |
| SCHEMBL21941044 | 0.70 | KDM5B (0.31) | WNT1GSK3BDYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023020209-A1 | UREA COMPOUND CONTAINING 2-HETEROAROMATIC RING SUBSTITUTION, PREPARATION METHOD THEREFOR AND USE THEREOF | 中国科学院上海药物研究所 | 2023-02-23 | — | — | WO | disclosed |
| WO-2021126316-A1 | MACROCYCLIC COMPOUNDS | ZENO MANAGEMENT, INC. (US) | 2021-06-24 | — | — | WO | disclosed |
| US-10329270-B2 | Heteroaryl compounds as BTK inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2019-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10329270-B2 | Heteroaryl compounds as BTK inhibitors and uses thereof | BTK, SYK, LCK | LRRK2 306/4885PRMT5 1276/4885WDR77 1337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.